![logo](/logos/CVAC.webp)
CureVac N.V.
NASDAQ:CVAC
2.74 (USD) • At close September 6, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | CureVac N.V. |
Symbool | CVAC |
Munteenheid | USD |
Prijs | 2.74 |
Beurswaarde | 614,598,440 |
Dividendpercentage | 0% |
52-weken bereik | 2.215 - 8.93 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Alexander Zehnder M.B.A., M.D. |
Website | https://www.curevac.com |
An error occurred while fetching data.
Over CureVac N.V.
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)